Can-Fite Biopharma GAAP EPS of -$5.97, revenue of $0.41M
Source: SeekingAlpha
2026-03-26 09:29:57 ET
More on Can-Fite Biopharma
- Seeking Alpha’s Quant Rating on Can-Fite Biopharma
- Historical earnings data for Can-Fite Biopharma
- Financial information for Can-Fite Biopharma
Read the full article on Seeking Alpha
For further details see:
Can-Fite Biopharma GAAP EPS of -$5.97, revenue of $0.41M
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)
NASDAQ: CANF
CANF Trading
4.24% G/L:
$3.07 Last:
26,347,625 Volume:
$3.65 Open:
CANF Latest News
April 30, 2026 08:31:35 am
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
March 30, 2026 07:20:00 am
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
March 26, 2026 09:27:54 am
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
March 17, 2026 07:47:08 am
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
CANF Stock Data
$9,110,276,106
1,960,466,988
N/A
3
N/A
Biotechnology & Life Sciences
Healthcare
IL
Ramat Gan
